Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Therapeutic chemokine receptor antagonists |
| Inventors: | Clark-Lewis, Ian; Vancouver, Canada Gong, Jiang-Hong; Vancouver, Canada Duronio, Vincent; Delta, Canada Clark-Lewis, Ian; Vancouver, Canada Gong, Jiang-Hong; Vancouver, Canada Duronio, Vincent; Delta, Canada |
| Summary: | This invention provides a variety of therapeutic uses for CXCR4 antagonists, which are typically used for reducing interferon gamma production by T-cells in the treatment of cancer and of autoimmune diseases such as multiple sclerosis, and for the inhibition of angiogenesis. This invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation and with an excipient or carrier, the exact nature of which is disclosed. The CXCR4 antagonists for use in this invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1. |
| Abstract: | The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments. CXCR4 antagonsits may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6946445 |
| Application Number: | US1999000646192 |
| Date Filed: | 12/02/1999 |
| Date Published: | 20/09/2005 |
| Assignee: | The University of British Columbia, Vancouver, Canada |